Trial Profile
Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Dexrazoxane (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Methotrexate (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 13 Oct 2021 Results of pooled analysis (n=1308) assessing long-term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane-containing clinical trials (P9404, P9425, P9426, DFCI 95-01 and P9754), published in the Cancer.
- 31 May 2020 Results (N=173), subgroup analysis of data pooled from 5 randomized trials (P9404, P9425, P9426, DFCI 95-01 and P9754) assessing cardiac function in long-term survivors , plus a matched group of osteosarcoma survivors treated with Doxorubicin alone, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 16 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.